The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
Comparison Chart: Antiviral Drugs for Influenza for 2021-2022 (online only)
Download PDF:   US English
Med Lett Drugs Ther. 2022 Jan 10;64(1641):e1-5
Disclosures
Principal Faculty
  • Mark Abramowicz, M.D., President: no disclosure or potential conflict of interest to report
  • Jean-Marie Pflomm, Pharm.D., Editor in Chief: no disclosure or potential conflict of interest to report
  • Brinda M. Shah, Pharm.D., Consulting Editor: no disclosure or potential conflict of interest to report
  • F. Peter Swanson, M.D., Consulting Editor: no disclosure or potential conflict of interest to report
Objective(s)
Upon completion of this activity, the participant will be able to:
  1. Discuss the 2021-2022 recommendations for antiviral treatment and prophylaxis of seasonal influenza.
 Select a term to see related articles  Antiviral drugs   baloxavir   Flumist   influenza   influenza vaccine   Neuraminidase inhibitors   oseltamivir   peramivir   Rapivab   Relenza   Tamiflu   Xofluza   zanamivir 

View the Comparison Chart: Antiviral Drugs for Influenza for 2021-2022

Download PDF: US English

© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
arrow to previous article
arrow to next article